Functional assessment by myocardial performance index (Tei index) correlates with plasma brain natriuretic peptide concentration in patients with hypertrophic cardiomyopathy

Circulation Journal

Volumn 69, Issue 8, 2005, Pages 951-957

  Okawa, Makoto ^a   Kitaoka, Hiroaki ^a   Matsumura, Yoshihisa ^a   Kubo, Toru ^a   Yamasaki, Naohito ^a   Furuno, Takashi ^a   Doi, Yoshinori ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Brain natriuretic peptide; Cardiac function; Hypertrophic cardiomyopathy; Tei index

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; HEART CONTRACTION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE RELAXATION; HEART PERFORMANCE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; DIASTOLE; FEMALE; HEART FUNCTION TESTS; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; MYOCARDIAL CONTRACTION; NATRIURETIC PEPTIDE, BRAIN; SYSTOLE;

EID: 23744480227     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.951     Document Type: Article

References (44)

1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). J Am Coll Cardiol 2003; 42: 1687-1713.
2. Maron BJ. Hypertrophic cardiomyopathy: Systematic review. JAMA 2002; 287: 1308-1320.
3. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.
4. Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987; 10: 733- 742.
5. Chikamori T, Dickie S, Poloniecki JD, Myers MJ, Lavender JP, McKenna WJ. Prognostic significance of radionuclide-assessed diastolic function in hypertrophic cardiomyopathy. Am J Cardiol 1990; 65: 478-482.
6. Hirota Y, Furubayashi K, Kaku K, Shimizu G, Kino M, Kawamura K, et al. Hypertrophic nonobstructive cardiomyopathy: A precise assessment of hemodynamic characteristics and clinical implications. Am J Cardiol 1982; 50: 990- 997.
7. Okeie K, Shimizu M, Yoshio H, Ino H, Yamaguchi M, Matsuyama T, et al. Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2000; 36: 856-863.
8. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987; 59: 123-129.
9. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998; 81: 1339-1344.
10. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, et al. New index of combined systolic and diastolic myocardial performance: A simple and reproducible measure of cardiac function: A study in normal and dilated cardiomyopathy. J Cardiol 1995; 26: 357-366.
11. Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic dilated cardiomyopathy. Am J Cardiol 1998; 82: 1071-1076.
12. Tei C, Dujardin KS, Hodge DO, Kyle RA, Tajik AJ, Seward JB. Doppler index combining systolic and diastolic myocardial performance: Clinical value in cardiac amyloidosis. J Am Coll Cardiol 1996; 28: 658-664.
13. Bruch C, Schmermund A, Marin D, Katz M, Bartel T, Schaar J, et al. Tei-index in patients with mild-to-moderate congestive heart failure. Eur Heart J 2000; 21: 1888-1895.
14. Veslka J, Honek T. Early remodeling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol 2003; 88: 27-32.
15. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993; 88: 372-380.
16. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, Oda H, et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996; 28: 1234-1242.
17. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 2004; 109: 984-989.
18. Ogino K, Ogura K, Kinugawa T, Osaki S, Kato M, Furuse Y, et al. Neurohumoral profiles in patients with hypertrophic cardiomyopathy: Differences to hypertensive left ventricular hypertrophy. Circ J 2004; 68: 444-450.
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A, The Committee on MMode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
20. Shiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al, American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-367.
21. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A wide-angle, two-dimensional echocardiographic study of 125 patients. Am J Cardiol 1981; 48: 418-428.
22. Thaman R, Gimeno JR, Reith S, Tome Esteban MT, Limongelli G, Murphy RT, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol 2004; 44: 398-405.
23. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, et al. Hypertrophic cadiomyopathy: The importance of the site and the extent of hypertrophy: A review. Prog Cardiovasc Dis 1985; 28: 1-83.
24. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
25. Appleton CP, Jensen JL, Hatle LK, Oh JK. Doppler evaluation of left and right ventricular diastolic function: A technical guide for obtaining optimal flow velocity recordings. J Am Soc Echocardiogr 1997; 10: 271-291.
26. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
27. Redfield M, Rodeheffer R, Jacobsen S, Mahoney D, Bailey K, Burnett J. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002; 40: 976- 982.
28. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355: 58-60.
29. Gwathmey JK, Warren SE, Briggs GM, Copelas L, Feldman MD, Phillips PJ, et al. Diastolic dysfunction in hypertrophic cardiomyopathy: Effect on active force generation during systole. J Clin Invest 1991; 87: 1023-1031.
30. Moon JC, McKenna WJ, McCrohon JA, Eliott PM, Smith GC, Pennel DJ. Toward clinical assessment in hypertrophic cardiomyopathy with Gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-1567.
31. Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, et al. Analysis of chronic heart failure registry in the Tohoku district: Third year follow-up. Circ J 2004; 68: 427-434.
32. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-322.
33. Kitaoka H, Takata J, Hitomi N, Furuno T, Doi YL. Natriuretic peptides and contractile reserve in dilated cardiomyopathy. Lancet 1998; 352: 487.
34. Mizuno Y, Yoshimura M, Harada E, Nakayama M, Sakamoto T, Shimasaki Y, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 2000; 86: 1036-1040.
35. Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 1657-1663.
36. Lorenzoni R, Gistri R, Cecchi F, Olivotto I, Chiriatti G, Elliott P, et al. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfucntion. Am Heart J 1998; 136: 972-981.
37. Ono M, Tanabe K, Asanuma T, Yoshitomi H, Shimizu H, Ohta Y, et al. Doppler echocardiography-derived index of myocardial performance (TEI index): Comparison with brain natriuretic peptide levels in various heart disease. Jpn Circ J 2001; 65: 632-642.
38. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
39. Zhang H, Otsuji Y, Matsukida K, Hamasaki S, Yoshihuku S, Kumanohoso T, et al. Noninvasive differentiation of normal from pseudonormal/restrictive mitral flow using TEI index combining systolic and diastolic function. Circ J 2002; 66: 831-836.
40. Zhang H, Otsuji Y, Matsukida K, Hamasaki S, Yoshihuku S, Kumanohoso T, et al. Noninvasive estimation of left ventricular diastolic filling pressure from Doppler Tei index. J Echocardiogr 2003; 1: 15-22.
41. Briguori C, Betocchi S, Manganelli F, Gigante B, Losi MA, Ciampi Q, et al. Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. Eur Heart J 2001; 22: 1328-1336.
42. Haque A, Otsuji Y, Yoshifuku S, Kumanohoso T, Zhang H, Kisanuki A, et al. Effects of valve dysfunction on Doppler Tei index. J Am Soc Echocardiogr 2002; 15: 877-883.
43. Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH III, Zoghbi WA, Quiones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999; 99: 254-261.
44. Matsumura Y, Elliott PM, Virdee MS, Sorajja P, Doi Y, McKenna WJ. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: Relation to symptoms and exercise capacity. Heart 2002; 87: 247-251.